Hexima Ltd

Hexima Limited (Hexima) is an Australia-based biotechnology company. The Company is engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). The Company is conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis. The Company holds granted, long-life patents protecting HXP124 in markets globally.